Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden; Kolding Hospital, Department of Neurology, Kolding, Denmark.
Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden; The Karolinska Neuroimmunology & Multiple Sclerosis Centre, Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Mult Scler Relat Disord. 2024 Jul;87:105637. doi: 10.1016/j.msard.2024.105637. Epub 2024 May 1.
Few studies have examined the effect of concomitant autoimmune diseases on multiple sclerosis (MS) disability worsening. We set out to examine whether concomitant Crohn's Disease (CD), Ulcerative Colitis (UC), or Type 1 Diabetes (T1D) affect MS disability worsening in a nationwide cohort of MS patients as defined by reaching expanded disability scale status (EDSS) scores 3.0, 4.0 and 6.0.
Patients with MS onset between January 2004 and January 2019 were identified from the Swedish MS registry and the Swedish National Patient Register. Kaplan-Meier analysis was used to estimate the median time to reach sustained disability milestones. Adjusted Cox proportional hazard regression models were used to calculate the risk of reaching disability milestones among persons with and without CD, UC, or T1D.
Out of 8972 persons with MS, 88 (1.0 %) had T1D, 47 (0.8 %) had UC, and 78 (0.9 %) had CD. There was a significantly higher risk of disability progression, for persons with MS and T1D for reaching EDSS 6.0, hazard ratio (HR) = 2.21 (95 % confidence interval (CI) = 1.48 -3.31) and persons with MS and comorbid CD for reaching EDSS 3.0, HR = 2.30 (95 %CI = 1.74-3.04) and 4.0, HR = 1.59 (95 %CI = 1.09-2.32), and persons with MS and comorbid UC for reaching EDSS 3.0 HR = 1.57 (95 %CI = 1.15-2.14). As defined by Charlson's comorbidity index, the co-existence of other co-morbidities conferred a significant increase in the risk of reaching all endpoints, with HR ranging from 1.23 to 1.62.
Comorbidity is associated with a significantly increased risk of reaching disability end-points, and T1D, CD, and UC increase the risk further. Thus, there appears to be a need for increased vigilance of comorbidites in persons with MS in order to optimise the long-term outcome of MS.
很少有研究探讨合并自身免疫性疾病对多发性硬化症(MS)残疾恶化的影响。我们着手研究在全国性的 MS 患者队列中,是否合并克罗恩病(CD)、溃疡性结肠炎(UC)或 1 型糖尿病(T1D)会影响 MS 残疾恶化,这是根据扩展残疾量表(EDSS)评分达到 3.0、4.0 和 6.0 来定义的。
从瑞典 MS 登记处和瑞典国家患者登记处确定 2004 年 1 月至 2019 年 1 月间发病的 MS 患者。使用 Kaplan-Meier 分析来估计达到持续残疾里程碑的中位时间。使用调整后的 Cox 比例风险回归模型计算有和没有 CD、UC 或 T1D 的患者达到残疾里程碑的风险。
在 8972 名 MS 患者中,88 名(1.0%)患有 T1D,47 名(0.8%)患有 UC,78 名(0.9%)患有 CD。MS 患者合并 T1D 达到 EDSS 6.0 的残疾进展风险显著升高,风险比(HR)=2.21(95%置信区间(CI)=1.48-3.31),MS 患者合并合并 CD 达到 EDSS 3.0 的风险升高,HR=2.30(95%CI=1.74-3.04)和 4.0,HR=1.59(95%CI=1.09-2.32),MS 患者合并 UC 达到 EDSS 3.0 的风险升高,HR=1.57(95%CI=1.15-2.14)。根据 Charlson 合并症指数,其他合并症的存在显著增加了达到所有终点的风险,风险比范围为 1.23 至 1.62。
合并症与达到残疾终点的风险显著增加相关,T1D、CD 和 UC 进一步增加了这种风险。因此,在 MS 患者中似乎需要增加对合并症的监测,以优化 MS 的长期预后。